Beijing Saiseng Pharmaceutical Co., Ltd. announces the profit distribution plan for the year 2025. The company and all members of the board guarantee that the information disclosed is true, accurate, and complete, without false records, misleading statements, or significant omissions.
I. Review Procedure
On March 29, 2026, the company held the 13th meeting of the 5th Board of Directors, where the proposal for the "2025 Profit Distribution Plan" was approved and agreed to be submitted to the company's 2025 annual shareholders' meeting for review and implementation upon approval.
II. Basic Situation of Profit Distribution
According to the audit by Zhitong Accounting Firm (Special General Partnership), the net profit attributable to shareholders of the listed company in the consolidated financial statements for 2025 is RMB 14,570,990.82, while the net profit of the parent company for 2025 is RMB 48,201,296.27. In accordance with the Company Law and the Articles of Association, when the cumulative amount of statutory surplus reserves reaches 50% of the registered capital, no further statutory surplus reserves need to be extracted. Therefore, no statutory surplus reserves were extracted this year. As of December 31, 2025, the undistributed profits in the consolidated financial statements amount to RMB 1,797,951,199.89, and the cumulative undistributed profits of the parent company amount to RMB 1,932,657,897.54.